We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company opera... Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services. Show more
Aptorum Group Limited (NASDAQ: APM) (βAptorum Groupβ or the βCompanyβ), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious...
Aptorum Group Limited (Nasdaq: APM) (βAptorum Groupβ or βWeβ), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.42 | 55.2631578947 | 0.76 | 1.2864 | 0.7102 | 50740 | 0.945619 | CS |
4 | 0.48 | 68.5714285714 | 0.7 | 1.2864 | 0.6521 | 51653 | 0.83582993 | CS |
12 | -0.7106 | -37.5859515498 | 1.8906 | 2 | 0.46 | 43796 | 0.94392921 | CS |
26 | -3.18 | -72.9357798165 | 4.36 | 4.74 | 0.46 | 28270 | 1.51006105 | CS |
52 | -1.15 | -49.356223176 | 2.33 | 17.49 | 0.46 | 622023 | 8.257245 | CS |
156 | -15.12 | -92.7607361963 | 16.3 | 23.5 | 0.46 | 490967 | 12.41211132 | CS |
260 | -141.92 | -99.1754018169 | 143.1 | 182.5 | 0.46 | 486175 | 21.1117175 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions